ADVERTISEMENT

U.S. FDA Completes Inspection Of Aleor Derma’s Karakhadi Unit: Alembic Pharma

Aleor Dermaceuticals is a 60:40 Joint Venture between Alembic Pharmaceuticals and Orbicular Pharmaceutical Technologies.

Capsules pass along the production line during manufacture (Photographer: Dhiraj Singh/Bloomberg)
Capsules pass along the production line during manufacture (Photographer: Dhiraj Singh/Bloomberg)

Drug firm Alembic Pharmaceuticals on Wednesday said its joint venture firm Aleor Dermaceuticals has successfully completed the inspection of Karakhadi facility in Gujarat by the U.S. health regulator.

Aleor Dermaceuticals is a 60:40 Joint Venture between Alembic Pharmaceuticals and Orbicular Pharmaceutical Technologies, the company said in a BSE filing.

The JV has completed United States Food and Drug Administration inspection at its formulation manufacturing facility at Karakhadi without any observations, it added.

The inspection was carried out from Jan. 6 to Jan. 8, 2020, Alembic said.

Shares of Alembic Pharmaceuticals closed at Rs 552 apiece on BSE, down 0.80 percent from its previous close.